Chunghwa Chemical Synthesis & Biotech Co Ltd

Chunghwa Chemical Synthesis & Biotech Co., Ltd. researches, develops, manufactures, and sells active pharmaceutical ingredients (APIs) in Taiwan, the United States, India, Greece, Croatia, Japan, and other international markets. Its product portfolio includes antifungal, immunosuppressant, oncology, cardiovascular, peptide, immunomodulating, statin, muscle relaxant, and ACE inhibitor APIs, many with complete DMF or COS. The company also offers specialty immunosuppressant APIs such as mycophenolate mofetil, rapamycin, and tacrolimus; rapamycin derivatives including everolimus, temsirolimus, zotarolimus, and biolimus; and echinocandins comprising caspofungin, micafungin, and anidulafungin. In addition, it provides contract manufacturing and research services and exports its products. Formerly known as China Chemical Synthesis Industry Co., Ltd., it changed its name to Chunghwa Chemical Synthesis & Biotech Co., Ltd. in January 2003. Founded in 1964, the company is headquartered in New Taipei City, Taiwan.